These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34789400)

  • 1. The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China.
    Chen Q; Zhong R; Dong K; Wang Y; Kui Y; Ma B; Wen X; Jin Q
    Dig Liver Dis; 2022 Aug; 54(8):1094-1100. PubMed ID: 34789400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms.
    Wang X; Yang Z; Ran Y; Li L; Wang B; Zhou L
    Ann Hepatol; 2023; 28(5):101121. PubMed ID: 37302574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis.
    Haldar D; Janmohamed A; Plant T; Davidson M; Norman H; Russell E; Serevina O; Chung K; Qamar K; Gunson B; Hansen B; Richter A; Trivedi PJ; Hirschfield GM
    Liver Int; 2021 Mar; 41(3):535-544. PubMed ID: 33022821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
    Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
    J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical performance of AMA-M2, anti-gp210 and anti-sp100 antibody levels in primary biliary cholangitis: When detected by multiplex bead-based flow fluorescent immunoassay.
    Wang Z; Li Y; Ren L; Li Y; Xu T; Li W; Gao W; Sun G; Liu M
    Immun Inflamm Dis; 2024 Jan; 12(1):e1161. PubMed ID: 38270327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis.
    Nakamura M; Shimizu-Yoshida Y; Takii Y; Komori A; Yokoyama T; Ueki T; Daikoku M; Yano K; Matsumoto T; Migita K; Yatsuhashi H; Ito M; Masaki N; Adachi H; Watanabe Y; Nakamura Y; Saoshiro T; Sodeyama T; Koga M; Shimoda S; Ishibashi H
    J Hepatol; 2005 Mar; 42(3):386-92. PubMed ID: 15710222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators.
    Qian JD; Yao TT; Wang Y; Wang GQ
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):874-884. PubMed ID: 32305248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.
    Yang F; Yang Y; Wang Q; Wang Z; Miao Q; Xiao X; Wei Y; Bian Z; Sheng L; Chen X; Qiu D; Fang J; Tang R; Gershwin ME; Ma X
    Aliment Pharmacol Ther; 2017 Mar; 45(5):733-743. PubMed ID: 28083929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis.
    Huang C; Han W; Wang C; Liu Y; Chen Y; Duan Z
    Dis Markers; 2019; 2019():9121207. PubMed ID: 31737133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China.
    Chen S; Duan W; Li M; Li S; Lv T; Tian Q; Wang Q; Wu X; Zhao X; Wang X; Wang Y; Kong Y; Ma H; Ou X; You H; Jia J
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1236-1241. PubMed ID: 30365184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability.
    Melchor-Mendoza YK; Martínez-Benítez B; Mina-Hawat A; Rodríguez-Leal G; Duque X; Moran-Villota S
    Ann Hepatol; 2017; 16(3):430-435. PubMed ID: 28425413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of clinical characteristics in patients with gp210 antibody-positive primary biliary cholangitis].
    Huang CY; Liu YM; Liu H; Xu B; Yan HP; Zhang HP; Liao HY; Zhang XD; Zhao J; Li WJ; Duan ZP
    Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):419-425. PubMed ID: 35545568
    [No Abstract]   [Full Text] [Related]  

  • 13. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-gp210 and anti-Sp100 antibodies in primary biliary cholangitis.
    Ben Lamine Z; Ben Jazia I; Ben Ahmed M; Ben Slama A; Baccouche A; Slama F; Jemaa A; Ghedira I; Mankaï A
    Arab J Gastroenterol; 2021 Dec; 22(4):316-320. PubMed ID: 34090832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Anti-Hexokinase 1 Antibodies Are Associated With Poor Prognosis in Patients With Primary Biliary Cholangitis.
    Reig A; Norman GL; Garcia M; Shums Z; Ruiz-Gaspà S; Bentow C; Mahler M; Romera MA; Vinas O; Pares A
    Am J Gastroenterol; 2020 Oct; 115(10):1634-1641. PubMed ID: 32467507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
    Tanaka A; Hirohara J; Nakano T; Matsumoto K; Chazouillères O; Takikawa H; Hansen BE; Carrat F; Corpechot C
    J Hepatol; 2021 Sep; 75(3):565-571. PubMed ID: 33882268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    Corpechot C; Chazouillères O; Belnou P; Montano-Loza AJ; Mason A; Ebadi M; Eurich D; Chopra S; Jacob D; Schramm C; Sterneck M; Bruns T; Reuken P; Rauchfuss F; Roccarina D; Thorburn D; Gerussi A; Trivedi P; Hirschfield G; McDowell P; Nevens F; Boillot O; Bosch A; Giostra E; Conti F; Poupon R; Parés A; Reig A; Donato MF; Malinverno F; Floreani A; Russo FP; Cazzagon N; Verhelst X; Goet J; Harms M; van Buuren H; Hansen B; Carrat F; Dumortier J;
    J Hepatol; 2020 Sep; 73(3):559-565. PubMed ID: 32275981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of anti-gp210 or anti-sp100 antibodies in AMA-positive patients may help support a diagnosis of primary biliary cholangitis.
    Jaskowski TD; Nandakumar V; Novis CL; Palmer M; Tebo AE
    Clin Chim Acta; 2023 Feb; 540():117219. PubMed ID: 36610465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
    Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
    Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluctuations of antimitochondrial antibodies and anti-gp210 antibody in a patient with primary biliary cholangitis and Sjögren syndrome with subsequent autoimmune hemolytic anemia: A case report.
    Zhao DT; Liu YM; Han Y; Zhang HP; Zhao Y; Yan HP
    Medicine (Baltimore); 2020 Jan; 99(3):e18856. PubMed ID: 32011506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.